Fourth EU Opdivo Approval Pending, But BMS Won't Gain Much

If as is expected the EU Commission rubber-stamps CHMP approval for BMS' Opdivo in classical Hodgkin lymphoma, it will be the first PD-1 inhibitor approved to treat a hematologic malignancy in the EU.